New for old? Risperidone long-acting injection in older patients

Australasian Psychiatry

Volumn 15, Issue 6, 2007, Pages 461-464

  Hudson Jessop, Pamela ^a   Hughes, Brendan ^a   Brinkley, Neridah ^a  

^a NAMBOUR GENERAL HOSPITAL   (Australia)

Author keywords

Action preparation; Aged; Elderly patients; Psychotic disorders; Risperidone

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; FLUPENTIXOL; HALOPERIDOL; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; THYROXINE; VALPROIC ACID; ZUCLOPENTHIXOL;

AGED; AKATHISIA; ANTICHOLINERGIC EFFECT; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CONFUSION; DELUSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPOTHYROIDISM; INJECTION; LOW DRUG DOSE; MALE; MENTAL HEALTH; MUSCLE RIGIDITY; PARANOID SCHIZOPHRENIA; PHYSICAL EXAMINATION; PSYCHOSIS; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; TARDIVE DYSKINESIA; TREMOR;

AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 36248979096     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1080/10398560701616262     Document Type: Article

References (11)

1. Barak, Y., Shamir, E. and Weizman, R. (2002) Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. Journal of Clinical Pharmacology, 22, pp. 115-120.
2. Kane, JM, Eerdekens, M., Lindenmayer, JP, Keith, S., Lesem, M. and Karcher, K. (2003) Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotics. American Journal of Psychiatry, 160, pp. 1125-1132.
3. Moller, H-J, Llorca, P-M and Sacchetti, E. (2005) Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. International Clinical Psychopharmacology, 20, pp. 121-130.
4. Parellada, E., Abdrezina, R. and Milanova, V. (2005) Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Journal of Psychopharmacology, 19, pp. 5-14.
5. Niaz, OS and Haddad, PM. (2007) Thirty five months experience of risperidone long-acting injection in a UK psychiatric service including mirror-image analysis of in-patient care. Acta Psychiatrica Scandinavica, 116, pp. 36-46.
6. Brodaty, H., Ames, D. and Snowden, J. (2003) A randomised placebo-controlled trial of risperidone for the treatment of aggression, agitation and psychosis of dementia. Journal of Clinical Psychiatry, 64, pp. 134-143.
7. De Deyn, PP, Katz, IR, Brodaty, H., Lyons, B., Greenspan, A. and Burns, A. (2005) Management of agitation, aggression and psychosis associated with dementia: A pooled analysis including three randomised, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clinical Neurology and Neurosurgery, 107, pp. 497-508.
8. Madhusoodanan, S., Brecher, M. and Brenner, R. (1999) Risperidone in the treatment of elderly patients with psychotic disorders. American Journal of Geriatric Psychiatry, 7, pp. 132-138.
9. Lasser, R., Bossie, C. and Eerdekens, M. Stable elderly patients with psychotic disorders improve with long-acting risperidone (Risperdal Consta) [poster].
10. Gharabawi, G., Bossie, C. and Zhu, Y. An assessment of dyskinesia in high-risk patients receiving long-acting risperidone [poster].
11. Masand, PS and Gupta, S. (2003) Long acting injectable antipsychotics in the elderly: Guidelines for effective use. Drugs Aging, 20, pp. 1099-1110.